• Kabir Nath

    MA, MBA
    President & CEO, Otsuka North America Pharmaceutical Business

    Kabir Nath

    MA, MBA
    President & CEO, Otsuka North America Pharmaceutical Business

    Kabir is a senior commercial leader with more than 25 years of broad international biopharma and devices experience who has shaped strategy and delivered results in complex, challenging business environments at country, regional and global levels. He has lived and worked in the U.K., France, Spain, India, Singapore, China and the US. Kabir joined Otsuka to head the North American pharmaceutical business in March 2016, with direct responsibility for Otsuka America Pharmaceuticals, Inc., Avanir and Otsuka Canada. Before joining Otsuka, Kabir spent 13 years in leadership roles at Bristol Myers Squibb. Most recently he was Senior Vice President, Virology, Transplant & Optimized Brands, responsible for the commercialization of a significant portfolio – including drugs for HIV, hepatitis B and hepatitis C and immunosuppression in the USA. Previously he was Senior Vice President, Global Commercialization Virology & Neuroscience, leading global strategy for these two disease areas. In addition he served as interim head of Emerging Markets for much of 2012. Kabir joined BMS in Singapore in 2003 as vice president for South East Asia/Taiwan/HK and moved to Shanghai in 2005 as president of BMS China. In 2008, Kabir was appointed president, Asia Pacific Medicines, with responsibility for all commercial operations in 13 countries. Prior to joining BMS, Kabir spent 11 years at Smith & Nephew, the medical technology company, in senior operational and strategic roles in the U.K., Europe and Asia. Kabir holds an MA from King’s College, University of Cambridge, and an MBA with Distinction from INSEAD.
  • Louis Allesandrine

    VP, Oncology and Renal Sales & Marketing

    Louis Allesandrine

    VP, Oncology and Renal Sales & Marketing

    "At Otsuka, we drive innovation and creativity by following the company philosophy; Taking the Road Less Traveled. It helps us address unmet needs of patients, their caregivers, and healthcare professionals, keeping us focused on doing our part to provide better health worldwide."

    As Vice President of Oncology and Renal Sales & Marketing at Otsuka America Pharmaceutical, Inc. (OAPI) I am responsible for leading the strategic development and execution of our U.S.-based commercial oncology renal businesses. This includes the co-promotion of SPRYCEL® (dasatinib) with BMS and our clinical stage collaborations with Astex Pharmaceuticals, a member of The Otsuka Group. Our goal is to develop and bring novel cancer therapeutics to market; meeting the needs of patients, their care givers and healthcare professionals. I joined OAPI in 2017 after 25 years of commercial experience in the pharmaceutical industry. Prior to joining OAPI, I served 6 years as Vice President, Oncology Marketing at Boehringer Ingelheim. Earlier in my career I held a series of leadership positions in sales and marketing focused in the areas of oncology and urology specialty care. I received an M.B.A. degree from Quinnipiac University.
  • Kevin Donovan
    Kevin B. Donovan

    M.S.
    Sr. VP, Otsuka-People, Business Services & Communications

    Kevin Donovan

    Kevin B. Donovan

    M.S.
    Sr. VP, Otsuka-People, Business Services & Communications

    “Otsuka-people dare to dream and we take the road less traveled to influence the future.”

    As the Senior Vice President of Otsuka-People, Business Services & Communications at Otsuka America Pharmaceutical, Inc., (OAPI) I have responsibility for overseeing all human resources functions for the U.S. business. Before joining Otsuka in 2009, I was Director, Human Resources, U.S. Field Sales, at AstraZeneca, supporting a sales force of approximately 6,000 people. At AstraZeneca, I also held positions of Director, Global Human Resources Strategy, in London and Director, Human Resources, U.S. Operations. Earlier, I spent eight years at Bristol-Myers Squibb (BMS) and DuPont Pharmaceuticals Co., which was acquired by BMS. I have a B.S. degree from the University of Delaware and a Master’s degree in Organization Dynamics from the University of Pennsylvania.
  • Jennifer McGee, Esq.

    J.D.
    Chief Compliance Officer, VP, Ethics & Compliance

    Jennifer McGee, Esq.

    J.D.
    Chief Compliance Officer, VP, Ethics & Compliance

    As Chief Compliance Officer, I am responsible for ensuring that Otsuka America Pharmaceutical, Inc. and Otsuka Pharmaceutical Development & Commercialization, Inc. maintain a robust and effective ethics and compliance program.  I joined Otsuka in January 2011, as Senior Compliance Counsel, and assumed the responsibilities of Chief Compliance Officer in May 2015.  Prior to joining Otsuka, I worked as a litigator at a multinational law firm, focusing on defending pharmaceutical and medical device manufacturers in government investigations and lawsuits.  I also served in the United States Army for more than 13 years, trying more than 70 felony criminal trials, and remain in the United States Army Reserves.  I earned a B.A. degree from St. Lawrence University and a Juris Doctor degree from University of Maryland School of Law.
  • Innes Meldrum

    VP, CNS Marketing and Sales

    Innes Meldrum

    VP, CNS Marketing and Sales

    "My motivation for working at Otsuka is that most companies talk about innovation but at Otsuka it's part of the DNA. One of my favorite quotes is that "the definition of insanity is doing the same thing and expecting different results" by Albert Einstein. I believe strongly that the essence of marketing is effectively differentiating vs the competition and to do this requires adopting new approaches that challenge conventional thinking and by implication the status quo. Otsuka provides an environment that actively encourages this."

    As Vice President of the CNS & Cardio-Renal Marketing organization at Otsuka America Pharmaceutical, Inc. (OAPI) I am responsible for leading our Marketing and Sales teams to create, execute, and innovative differentiated marketing strategies and tactics. I also have responsibility for commercialization of our CNS & Cardio-Renal pipelines. I have more than 20 years of experience in executive strategic, marketing, sales and business operations in both the pharmaceutical and technology industries. I joined Otsuka in 2017. Prior to joining Otsuka, I spent 3 years at Orexo, as Head of US Sales and Marketing, focused on the Opioid Addiction market. Before this I worked in a variety of Global and US roles with Novartis and most recently was Head of Sales and Marketing of the U.S. NeuroPsychiatry business. Prior to this I spent 10 years working in the tech. industry with Nortel Networks, HP and Agilent Technologies focussed on developing solutions for the Wireless Telecomms industry. I earned a B.Eng. in Electrical and Electronic Engineering from Strathclyde University in Glasgow, Scotland.
  • Mary Michael

    VP, Congress Stakeholder Management & Patient Advocacy

    Mary Michael

    VP, Congress Stakeholder Management & Patient Advocacy

    “Otsuka embraces innovative thinking. It is not our slogan, but our calling to create patient-centered solutions for some of the toughest diseases in CNS, oncology, and more. We don’t shy away from problems. We embrace them to find solutions.”

    As Vice President of Patient Advocacy and Stakeholder Management at Otsuka America Pharmaceutical, Inc. (OAPI), I have the unique opportunity to work with trailblazing leaders both inside and outside the clinic walls to create innovative patient-centered solutions. It is my responsibility to understand how the world is changing across multiple disease categories, and I pull together the thoughts, ideas, and research from a global array of key opinion leaders, patient advocates, technologists, caregivers, and more to incubate novel business solutions. I am able to bring innovation to Otsuka by engaging with stakeholders from the world’s most prestigious medical centers to local advocacy chapters. Before coming to Otsuka, I spent nine years with Wyeth Pharmaceuticals in Opinion Leader and Advocacy Relations, where I developed and executed our Global Opinion Leader business strategies across the Specialty products portfolio. Prior to Wyeth, I was at Bristol-Myers Squibb for 13 years, in a variety of positions. At Otsuka, I have spearheaded the launch of the Global Council on Alzheimer’s Disease (GCAD), a collection of preeminent experts who influence the Alzheimer’s space, including science, medicine, technology, policy, advocacy, and caregiving. Through GCAD, I have jumpstarted technological innovation, framed a patient navigation model for Alzheimer’s, and helped improve communications between families and healthcare providers. I am a graduate of Virginia Tech as well as Singularity University.
  • Tifani L. McCann

    PhD
    VP and Chief Data Officer (CDO)

    Tifani L. McCann

    PhD
    VP and Chief Data Officer (CDO)

    As Vice President and Chief Data Officer of Otsuka America Pharmaceutical, Inc. (OAPI), I lead the team responsible for harnessing the organization’s existing data assets across all lines of business as well as procuring essential data from external sources and converting these into actionable insights. I guide the organization’s data science strategy to ensure these insights provide meaningful business value, so that they can be integrated into portfolio decision making, clinical trial design, business analytics and market research for commercial operations. I have more than 20 years of Pharma and CRO leadership experience which include building and transforming biometrics capabilities, organizations and clinical data systems. Before joining Otsuka in 2019, I served as Global Head of Biostatistics and Data Analytics at Covance. In this role, I led the biostatistics and statistical programming organizations as well as the risk-based monitoring and medical data review organizations. Prior to my experience at Covance, I was at Bristol-Myers Squibb serving in various roles of increasing responsibility including the Biometrics’ therapeutic area head for Immunosciences to leading the business operations of the Global Biometrics Sciences organization as well as Global Head of the Data Strategy and Solutions organization. I received my Ph.D. in Biostatistics from the Medical College of Virginia.
  • Edward Stelmakh
    Edward Stelmakh

    CPA, CMA
    Sr. VP, CFO

    Edward Stelmakh

    Edward Stelmakh

    CPA, CMA
    Sr. VP, CFO

    "My primary motivation for working at Otsuka is to help define and execute on our corporate strategic goals as we deal with continuously changing landscape of internal and external challenges and opportunities. I have a real passion for driving positive change and working in an environment where one can make significant impact across a broad spectrum of areas. I truly believe that the only constant in life is change and Otsuka’s success as an organization is hinged upon its willingness and ability to embrace changes occurring in the pharmaceutical industry landscape."

    As Senior Vice President and CFO at Otsuka America Pharmaceutical, Inc. (OAPI), I am responsible for Finance, IT, Pricing and Contracting, Strategic Sourcing and Business Services supporting the U.S. business, including Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Prior to joining Otsuka in 2015, I spent six years as Vice President, Finance, Clinical Development and Commercialization Services at Covance (a division of LabCorp), leading finance and commercial support functions of a global billion-dollar division with 5,000 employees worldwide. Prior to Covance, I held a variety of positions with growing responsibilities within Organon (Schering Plough), Mylan, Sanofi-Aventis and Johnson & Johnson. My background includes a broad spectrum of financial, commercial and operational leadership roles, including eight years of international assignments in the Netherlands and Russia.  I received a B.S. in Finance from Towson University, and an M.B.A. from University of Baltimore. I am also a Certified Public Accountant (New Jersey) and a Certified Management Accountant. I am an active member of the Princeton community and currently serve as Treasurer of the Arts Council of Princeton.
  • Steven Weis
    Steven J. Weisel, Esq.

    J.D.
    VP & General Counsel

    Steven Weis

    Steven J. Weisel, Esq.

    J.D.
    VP & General Counsel

    "Otsuka is committed to conducting business with integrity at all times. We strive to be creative and innovative without ever losing sight of the laws and regulations that govern our industry and the trust that doctors, patients, and their families have placed in us."

    As Vice President and General Counsel at Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC) I lead the Legal Affairs department, which provides legal counsel and support to OPDC and its sister company Otsuka America Pharmaceutical, Inc. (OAPI). Earlier at Otsuka, I held various leadership positions in Legal Affairs and Human Resources, such as Senior Director & Corporate Counsel, Senior Corporate Attorney, and Senior Human Resources Business Partner. I joined Otsuka in 2001 after a career in business that included overseeing human resources functions at a major commercial printing company and two technology companies. I earned a B.A. degree and a Juris Doctor degree from The George Washington University.
  • Andrew Wright
    Andrew Wright

    Vice President, Digital Medicine and Head of Expanded Collaboration Business Unit Company

    Andrew Wright

    Andrew Wright

    Vice President, Digital Medicine and Head of Expanded Collaboration Business Unit Company

    “Our journey with digital medicine was inspired by the late President of Otsuka, Dr. Taro Iwamoto. He drove the value of innovation. He challenged us to think differently about solving unmet healthcare needs through alliances and technology. We are working to fulfill this vision by going beyond the pill.”

    As Vice President of Digital Medicines, at Otsuka America Pharmaceutical, Inc. (OAPI) I am responsible for leading the commercialization of wearable computing and digital products. Our goal is to enable improved patient medication adherence and better-informed physician decision-making to tailor treatment to the patient’s needs. I have more than 25 years of U.S. and Global experience in commercial leadership roles in the pharmaceutical industry. Earlier, I worked at Novartis as Head, HCP Digital/Multi-Channel Marketing, Global Commercialization, and was responsible for identifying and developing digital and multi-channel solutions that enhanced customer engagement. Prior to that, as Executive Director, Insights & Innovation, I led and developed a team responsible for customer/brand insights and innovation across the U.S. pharmaceutical business. I also held senior marketing and sales roles for in-line and launch brands at Novartis, producing consistently strong results. At Pharmacia, I led the launch of a major product in 11 markets across Europe. My Bachelor of Science degree is in Business Administration from Crewe and Alsager College.
  • William Carson
    William H. Carson

    A.B., M.D.
    President & CEO, OPDC

    William Carson

    William H. Carson

    A.B., M.D.
    President & CEO, OPDC

    “Otsuka’s relentless pursuit of innovative solutions that address unmet patient needs while leveraging cutting edge technology enables us to deliver on our mission – developing new products for better health worldwide. The challenges in mental health and oncology are extensive and complex, but Otsuka-people are determined and committed to developing solutions. We have a robust and diverse pipeline that prepares us to meet the needs of today, and shape the world of tomorrow.”

    I am the President & CEO of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). My responsibilities include leading the team that develops new products and brings them to market, as well as creating strategic plans for the company’s product portfolio to ensure development programs meet quality and safety standards required by medical and regulatory agencies. Since my appointment in 2010, I have led the development efforts of compounds in neuroscience, cardio-renal, and oncology, and was instrumental in the development and registration of ABILIFY MAINTENA® (aripiprazole) for extended-release injectable suspension. I also helped guide the development and registration of SAMSCA® (tolvaptan), marking the first time Otsuka successfully developed and commercialized a product entirely on its own in the U.S. I joined Otsuka in 2002 as a board-certified psychiatrist and served as OPDC’s Senior Vice President, Global Clinical Development, overseeing the development of Otsuka-discovered compounds. During my career at Otsuka—and earlier at Bristol-Myers Squibb (BMS)—I was one of the key drivers in the development and commercialization of ABILIFY® (aripiprazole), which Otsuka marketed in collaboration with BMS. I received an A.B. degree in history and science from Harvard University and an M.D. degree from Case Western Reserve University.
  • Christoph Koenen

    M.D., MBA
    Sr. VP & Chief Medical Officer

    Christoph Koenen

    M.D., MBA
    Sr. VP & Chief Medical Officer

    As Senior Vice President and Chief Medical Officer of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), I help define the global R&D strategy and have direct responsibility for taking all compounds for global registration from first in human through to Regulatory Approval. As a seasoned clinical development leader, I work collaboratively across the leadership team to help refine the clinical development strategy and roadmap for implementation.  In addition, I have oversight of clinical management to ensure studies are completed on time and within budget. In my area, we continue to invest in new and innovative means of conducting clinical trials as well as other innovative ways of data collection.  My responsibilities include medical affairs which consists of medical strategy and field medical. In medical affairs we are the bridge between the research and the commercial part of the organization.   Before joining Otsuka in 2019, I was Head of Cardiovascular Medicine and Development at Bristol-Meyers Squibb (BMS). In this role I helped BMS to develop its next generation of cardiovascular medicines.  I was also responsible for ongoing data generation for Eliquis (one of the most successful drugs in the industry) and was a catalyst behind the creation of the largest Real World Evidence data generation initiative created in the field of anticoagulation. Prior to joining BMS in 2011, I worked for Novo Nordisk in various medical and development functions in Europe, as well as in the US. My dual medicine-business background has informed my ability to combine scientific innovation with a strategic approach to business-development opportunities, regulatory navigation, and global-patient access solutions.   I received my medical degree from Ruprecht-Karls University School of Medicine in Heidelberg, Germany, in 1994. I also hold a MBA from Schiller International University.  I am board certified in internal medicine and diabetology.
  • Robert McQuade
    Robert McQuade

    Ph.D.
    Executive VP & Chief Strategic Officer

    smaller image of bob mcquade

    Robert McQuade

    Ph.D.
    Executive VP & Chief Strategic Officer

    Otsuka is not right for everyone. It is a dynamic environment for those who wish to be challenged and engaged every day. We are focused on bringing important new drugs and innovations to patients, especially for those with serious mental illness. This has been my personal goal throughout my career and through Otsuka I believe that I have in fact made a difference in the lives of these patients.

    As Executive Vice President & Chief Strategic Officer at Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC) I am responsible for coordinating the development strategy for our compounds across their life cycle.   I have more than 30 years of experience in the discovery, development, and marketing of drugs for the treatment of mental illness. My career started as a post-doctoral fellow in central nervous system (CNS) research at Schering-Plough Pharmaceuticals and gradually advanced to Associate Director of CNS Pharmacology.  In this role, I supervised the biochemical pharmacology group in their efforts to discover new drugs for mental illness, including schizophrenia and Alzheimer’s disease. I next joined the Global Medical Affairs team at Bristol-Myers Squibb (BMS). While at BMS, I was responsible for various products, including psychiatric treatments for generalized anxiety disorder and major depressive disorder.  More importantly, I was part of the team that helped form the alliance between BMS and Otsuka for the development and commercialization of aripiprazole. It was only natural that I ultimately joined Otsuka in 2004 to oversee global medical affairs for ABILIFY® (aripiprazole).  My roles have grown over the years and now I am responsible for the global development strategy for Otsuka’s compounds in the CNS, cardio-renal and oncology therapeutic areas. In addition, I am involved in many of Otsuka’s external collaborations and business development initiatives. I received a B.S. degree from Davidson College and a Ph.D. from the University of North Carolina-Chapel Hill.
  • Mirza Rahman
    Mirza Rahman

    M.D., M.P.H., FAAFP, FACPM.
    Sr. VP, Clinical Safety & Pharmacovigilance, and Global Head of Pharmacovigilance

    Mirza Rahman

    Mirza Rahman

    M.D., M.P.H., FAAFP, FACPM.
    Sr. VP, Clinical Safety & Pharmacovigilance, and Global Head of Pharmacovigilance

    "At Otsuka, we recognize that drug safety is everyone’s business, not just the responsibility of the people working in Global Pharmacovigilance (GPV) and even as we seek to create new products for better health worldwide, all of us at Otsuka are focused on creating a world-class drug-safety organization, where patient safety is our highest priority."

    I am Senior Vice President, Clinical Safety & Pharmacovigilance, and the Global Head of Pharmacovigilance at Otsuka Pharmaceutical Development & Commercialization (OPDC), Inc. Shortly after joining Otsuka in 2013, I led the Otsuka Global Pharmacovigilance Reform Initiative, and currently lead all of Otsuka's pharmacovigilance operations globally. Additionally, I have been responsible for Global Medical Affairs activities at OPDC. I joined Otsuka from Merck Research Laboratories, where I was an Executive Director in the Clinical Risk Management/Global Safety department. There, I led a team that performed global pharmacovigilance and risk management activities for more than 425 Merck products. Prior to this, I was a Worldwide Vice President, Health Economics & Reimbursement at Ortho-Clinical Diagnostics, Johnson & Johnson. I earned an M.P.H. from Columbia University, an M.D. degree from the Stony Brook School of Medicine, and a B.S. degree from the Sophie Davis School of Biomedical Education at City College of the City University of New York. I am a Fellow of both the American Academy of Family Physicians (AAFP) and the American College of Preventive Medicine (ACPM), which in 2014 bestowed upon me their highest honor, the ACPM Distinguished Service Award.
  • Henrietta Ukwu
    Henrietta Ukwu

    M.D., FACP., FRAPS.
    Sr. VP & Global Head, Global Quality and Global Regulatory Affairs

    Henrietta Ukwu

    Henrietta Ukwu

    M.D., FACP., FRAPS.
    Sr. VP & Global Head, Global Quality and Global Regulatory Affairs

    "At Otsuka, there are no boundaries to aspirations, achievements and appetite for innovation to drive health care solutions and make a difference to humanity."

    As Senior Vice President and Global Head of Global Quality and Global Regulatory Affairs at Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC) I have responsibility for leading the global regulatory team, overseeing successful execution of regulatory activities and professional development of the team. My 23 years of professional global regulatory experience includes contributing to over 20 original new drug and biologics products development and approvals; enriching the regulatory profession through publications, including authoring the Global Regulatory Systems textbook and teaching and mentoring many successful regulatory professional protégés. My early regulatory career was spent at Merck, where I held increasingly senior regulatory leadership positions. At Wyeth Pharmaceuticals, I oversaw all therapeutic areas across all regions including responsibility for WHO and developing world countries. I joined Otsuka in 2013 from Pharmaceutical Product Development, LLC, having served as Senior Vice President, Head, Global Regulatory Affairs. I am a Fellow of the American College of Physicians (FACP) and Fellow of the Regulatory Affairs Professionals Society (FRAPS) and have received many awards for contributions to medicine and the pharmaceutical industry. My medical and surgical degrees are from the University of Jos School of Medicine in Nigeria, and I completed a postgraduate Internal Medicine residency at Baptist Hospital, University of Tennessee. My fellowship in Infectious Diseases was completed at the Vanderbilt University Medical Center in Nashville, Tennessee.
  • Edward Stelmakh
    Edward Stelmakh

    CPA, CMA
    Sr. VP, CFO

    Edward Stelmakh

    Edward Stelmakh

    CPA, CMA
    Sr. VP, CFO

    "My primary motivation for working at Otsuka is to help define and execute on our corporate strategic goals as we deal with continuously changing landscape of internal and external challenges and opportunities. I have a real passion for driving positive change and working in an environment where one can make significant impact across a broad spectrum of areas. I truly believe that the only constant in life is change and Otsuka’s success as an organization is hinged upon its willingness and ability to embrace changes occurring in the pharmaceutical industry landscape."

    As Senior Vice President and CFO at Otsuka America Pharmaceutical, Inc. (OAPI), I am responsible for Finance, IT, Pricing and Contracting, Strategic Sourcing and Business Services supporting the U.S. business, including Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Prior to joining Otsuka in 2015, I spent six years as Vice President, Finance, Clinical Development and Commercialization Services at Covance (a division of LabCorp), leading finance and commercial support functions of a global billion-dollar division with 5,000 employees worldwide. Prior to Covance, I held a variety of positions with growing responsibilities within Organon (Schering Plough), Mylan, Sanofi-Aventis and Johnson & Johnson. My background includes a broad spectrum of financial, commercial and operational leadership roles, including eight years of international assignments in the Netherlands and Russia.  I received a B.S. in Finance from Towson University, and an M.B.A. from University of Baltimore. I am also a Certified Public Accountant (New Jersey) and a Certified Management Accountant. I am an active member of the Princeton community and currently serve as Treasurer of the Arts Council of Princeton.
  • Steven Weis
    Steven J. Weisel, Esq.

    J.D.
    VP & General Counsel

    Steven Weis

    Steven J. Weisel, Esq.

    J.D.
    VP & General Counsel

    "Otsuka is committed to conducting business with integrity at all times. We strive to be creative and innovative without ever losing sight of the laws and regulations that govern our industry and the trust that doctors, patients, and their families have placed in us."

    As Vice President and General Counsel at Otsuka Pharmaceutical Development & Commercialization, Inc., (OPDC) I lead the Legal Affairs department, which provides legal counsel and support to OPDC and its sister company Otsuka America Pharmaceutical, Inc. (OAPI). Earlier at Otsuka, I held various leadership positions in Legal Affairs and Human Resources, such as Senior Director & Corporate Counsel, Senior Corporate Attorney, and Senior Human Resources Business Partner. I joined Otsuka in 2001 after a career in business that included overseeing human resources functions at a major commercial printing company and two technology companies. I earned a B.A. degree and a Juris Doctor degree from The George Washington University.

NEUROSCIENCE

Otsuka has been committed for more than 3 decades to developing novel drugs for neurological conditions.